Skip to main content

Table 4 Biologic therapeutics in use or in development for use in juvenile idiopathic arthritis (JIA)

From: Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis

Drug

Target

FDA approval for JIA

Route

Dosage options

Etanercept

(Enbrel)

TNFα

Polyarticular JIA ages 2 years and older

Subcutaneous injection

0.8 mg/kg/dose once a week, maximum 50 mg/dose

Infliximab

(Remicade)

TNFα

No

Intravenous infusion

6 to 10 mg/kg/dose weeks 0, 2 and 6; then every 4 to 8 weeks

Adalimumab

(Humira)

TNFα

Polyarticular JIA ages 4 years and older

Subcutaneous injection

24 mg/m2 every 2 weeks, maximum 40 mg/dose

Anakinra

(Kineret)

IL-1

No

Subcutaneous injection

1 to 2 mg/kg/day, maximum 100 mg/dose

Rilonacept

(IL-1 Trap)

IL-1

No

Subcutaneous injection

2.2 to 4.4 mg/kg once a week

Abatacept

(Orencia)

Cytotoxic T-lymphocyte- associated antigen 4

Polyarticular JIA ages 6 years and older

Intravenous infusion

10 mg/kg weeks 0, 2 and 4; then every 4 weeks, maximum 1,000 mg/dose

Rituximab

(Rituxan)

CD20

No

Intravenous infusion

750 mg/m2; two doses 2 weeks apart or 375 mg/m2; four doses, weekly × 4, maximum 1,000 mg/dose

Tocilizumab

(MRA)

IL-6

No

Intravenous infusion

8 to 12 mg/kg every 2 weeks

  1. FDA, Food and Drug Administration.